bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology Read more about bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma Read more about Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
bluebird bio to Present at the Evercore ISI HealthCONx Conference Read more about bluebird bio to Present at the Evercore ISI HealthCONx Conference
bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting Read more about bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting
bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia Read more about bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia